Skip to main content
OpenTrials
Completed

NCT Number: NCT01236001

Belgian Drug-utilization Study to Evaluate the Use of VIMPAT® as Adjunctive Treatment of Partial Onset Seizures in Subjects Aged 16 and Older

Observational study at the request of the Belgian Institut National d'Assurance Maladie-Invalidité / Rijksinstituut voor Ziekte-en Invaliditeits Verzekering INAMI/RIZIV:

* type of patient treated with VIMPAT® * VIMPAT® dose * Effect of VIMPAT® on evolution of seizure control * Persistence rate at 6 months in terms of treatment duration * Discontinuation rate * Description of any changes in other epilepsy therapies * Safety and tolerability

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Seizures Nervous System Diseases Neurologic Manifestations Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

16 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Aalst, Belgium

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • An Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written Informed Consent form
  • Subject/legal representative is considered reliable and capable of adhering to the medication intake according to the judgement of the investigator
  • Based on the investigators clinical judgement, the subjects' seizure activity is uncontrolled on current therapy and it is in the subjects' best interest to be prescribed an antiepileptic drug (AED) as adjunctive therapy. The choice to prescribe VIMPAT® as adjunctive therapy is made by the treating investigator
  • The subject is aged 16 or older
  • The subject has a diagnosis of epilepsy with partial-onset seizures according to the label
  • The subject has a medication history with at least 3 AED therapies (lifetime and/or concomitant) with treatment failure: due to insufficient efficacy, due to significant adverse events
  • Sufficient data on the clinical situation before start of VIMPAT® and information on VIMPAT® dosing are present in the subject's medical record for patients on treatment with VIMPAT® at the time of enrollment into the study

Exclusion criteria

  • The subject has previously participated in this study or has participated in a clinical trial within the last 2 months
  • The subject has a history of chronic alcohol or drug abuse within the last 6 months
  • The subject has any medical or psychiatric condition that, in the opinion of the investigator, could jeopardize or would compromise the subject's ability to participate in this study
  • The subject has a known hypersensitivity and/or allergy to soya, peanuts, or any component of VIMPAT®
  • The subject is pregnant or lactating
  • The subject has a known AV-block degree 2 or 3
  • The subject is expected to be insufficiently compliant with contraception.
  • The subject has a history of suicide attempt, has received professional counseling for suicidal ideation, or is currently experiencing active suicidal ideation

Treatment and study plan

Lacosamide

Drug

Other names: VIMPAT®

Primary outcomes

  1. Mean Total Daily Dose of VIMPAT® (mg) at Baseline

    Time frame: Baseline

    Mean total daily dose at baseline will be only provided for subjects who were already treated by VIMPAT® at Baseline.

  2. Mean Total Daily Dose of VIMPAT® (mg) at 3 Months

    Time frame: 3 months

  3. Mean Total Daily Dose of VIMPAT® (mg) at 6 Months

    Time frame: 6 months

  4. Galenic Formulation Repartition in Subjects Treated by VIMPAT® at Baseline

    Time frame: Baseline

    This outcome will be only provided for subjects who were already treated by VIMPAT® at Baseline.

    VIMPAT is available as tablet and oral solution formulation in Belgium. The use of each galenic formulation will be presented with number of subjects by formulation.

  5. Galenic Formulation Repartition in Subjects Treated by VIMPAT® at 3 Months

    Time frame: 3 months

    VIMPAT is available as tablet and oral solution formulation in Belgium. The use of each galenic formulation will be presented with number of subjects by formulation.

  6. Galenic Formulation Repartition in Subjects Treated by VIMPAT® at 6 Months

    Time frame: 6 months

    VIMPAT is available as tablet and oral solution formulation in Belgium. The use of each galenic formulation will be presented with number of subjects by formulation.

Secondary outcomes

  1. Percentage of Subjects Who Received Concomitant Antiepileptic Drug Treatment

    Time frame: From baseline to study termination (6 months)

    Concomitant antiepileptic drug (AED) treatments are defined as treatments which started after or at the date of the first administration of VIMPAT®.

  2. Treatment Persistence of VIMPAT® After 6 Months

    Time frame: >=6 months

    Treatment persistence is defined as the percentage of subjects being treated under VIMPAT® after a given duration (>=6 months).

  3. Percentage of Subjects by Category of Clinical Evolution of Seizure Control at Baseline

    Time frame: Baseline

    This outcome will be only provided for subjects who were already treated by VIMPAT® at Baseline.

    Clinical evolution of seizures following administration of VIMPAT compared to baseline before start of VIMPAT. The evolution of seizure control is subjectively assessed by the investigator on a four categorical scale, with options being 1=worsened, 2=stable, 3=improved, 4=much improved. If seizure control is worse, the investigator will try to document the reason.

  4. Percentage of Subjects by Category of Clinical Evolution of Seizure Control at 3 Months

    Time frame: 3 months

    Clinical evolution of seizures following administration of VIMPAT compared to baseline before start of VIMPAT. The evolution of seizure control is subjectively assessed by the investigator on a four categorical scale, with options being 1=worsened, 2=stable, 3=improved, 4=much improved. If seizure control is worse, the investigator will try to document the reason.

  5. Percentage of Subjects by Category of Clinical Evolution of Seizure Control at 6 Months

    Time frame: 6 months

    Clinical evolution of seizures following administration of VIMPAT compared to baseline before start of VIMPAT. The evolution of seizure control is subjectively assessed by the investigator on a four categorical scale, with options being 1=worsened, 2=stable, 3=improved, 4=much improved. If seizure control is worse, the investigator will try to document the reason

Sponsors and collaborators

Lead sponsor

UCB Pharma

Industry

Registry information

Official study title

Multi-center, Observational, Drug-utilization Study in Belgium to Evaluate the Use of VIMPAT® in Clinical Practice as Adjunctive Treatment of Partial Onset Epilepsy in Subjects Aged 16 and Older.

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Nov 8, 2010
Registry last updated
Aug 8, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.